Today: 22 March 2026
Browse Category

NYSE:CANF 18 November 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma shares surged over 30% Tuesday after reporting a patient with advanced hepatocellular carcinoma remained cancer-free for nine years on its drug Namodenoson. The company also began enrolling patients in a pivotal Phase III trial for the treatment in Israel, Europe, and the U.S. Namodenoson holds Orphan Drug and Fast Track designations.

Stock Market Today

  • Rolls-Royce Shares Face Mixed Outlook Amid Middle East War Impact
    March 22, 2026, 6:07 AM EDT. Rolls-Royce (LSE: RR) shares slipped 10% over the past month after a strong rally. Geopolitical tensions in the Middle East have pushed energy prices higher, disrupting flights and the global economy. The company's defence division may see increased demand due to rising military budgets in Europe. Its work on mini-nuclear reactors offers long-term growth potential amid energy insecurity. However, aviation remains a key risk: disruption to flights reduces revenue from engine servicing contracts. British Airways' flight suspensions to Dubai highlight these challenges. The wider economic slowdown from elevated oil prices could further dampen air travel demand. Rolls-Royce's exposure to AI-driven demand via data centre power systems also faces uncertainty amid rising interest rates. The stock's valuation has corrected but remains elevated. Analysts suggest cautious, long-term investment amid mixed factors shaped by the evolving Middle East conflict.
Go toTop